Personnel Information

写真a

SASAKI Ritsuko


Job title

Assistant Professor
To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2025.07
    -
    Now
    Institute of Science Tokyo， -， Graduate Schools， Systemic Organ Regulation， Department of Specialized Surgeries， Assistant Professor
To the head of this page.▲

Research Areas 【 display / non-display 】

  • Tumor diagnostics and therapeutics

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Onagi H, Horimoto Y, Sakaguchi A, Ikarashi D, Yanagisawa N, Nakayama T, Nakatsura T, Ishizuka Y, Sasaki R, Watanabe J, Saito M, Saeki H, Hayashi T, Arakawa A, Yao T, Kitano S. High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast cancer research : BCR. 2022.10; 24 (1): 67. ( PubMed, DOI )

  2. Sasaki Ritsuko, Kurebayashi Nagomi, Eguchi Hidetaka, Horimoto Yoshiya, Shiga Takahiro, Miyazaki Sakiko, Kashiyama Taku, Akamatsu Wado, Saito Mitsue. トラスツズマブ誘発性の重篤心毒性におけるカリクレイン-PAR2-炎症促進性経路の関与(Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity) Cancer Science. 2022.10; 113 (10): 3449-3462. ( ichushi )

  3. Sasaki Ritsuko, Horimoto Yoshiya, Saeki Harumi, Sato Shoji, Sano Katsuhiro, Shikama Naoto, Ueno Mayumi, Saito Mitsue, Arai Masami. Li-Fraumeni症候群の診療から得られた知見　LFS関連乳癌の治療戦略とサーベイランスシステムの確立(Lessons Learned in Practice with Li-Fraumeni Syndrome: LFS-Related Breast Cancer Treatment Strategy and Establishment of a Surveillance System) 順天堂醫事雑誌. 2022.08; 68 (4): 405-412. ( ichushi )

  4. Sasaki R, Kurebayashi N, Eguchi H, Horimoto Y, Shiga T, Miyazaki S, Kashiyama T, Akamatsu W, Saito M. Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity. Cancer science. 2022.07; 113 (10): 3449-3462. ( PubMed, DOI )

  5. Sasaki R, Horimoto Y, Yanai Y, Kurisaki-Arakawa A, Arakawa A, Nakai K, Saito M, Saito T. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer. Anticancer research. 2021.04; 41 (4): 2133-2140. ( PubMed, DOI )

  6. Horimoto Y, Sasahara N, Sasaki R, Hlaing MT, Sakaguchi A, Saeki H, Arakawa A, Himuro T, Saito M. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. Breast cancer research and treatment. 2020.08; 183 (1): 41-48. ( PubMed, DOI )

  7. Myojin M, Horimoto Y, Ito M, Kitano S, Ishizuka Y, Sasaki R, Uomori T, Himuro T, Murakami F, Nakai K, Iijima K, Saito M. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast cancer (Tokyo, Japan). 2020.07; 27 (4): 732-738. ( PubMed, DOI )

  8. Horimoto Yoshiya, Hlaing May Thinzar, Saeki Harumi, Kitano Shigehisa, Nakai Katsuya, Sasaki Ritsuko, Kurisaki-Arakawa Aiko, Arakawa Atsushi, Otsuji Naomi, Matsuoka Shuji, Tokuda Emi, Arai Masami, Saito Mitsue. リンパ球優位型の乳癌におけるマイクロサテライト不安定性とミスマッチ修復蛋白の発現(Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer) Cancer Science. 2020.07; 111 (7): 2647-2654. ( ichushi )

  9. Horimoto Y, Thinzar Hlaing M, Saeki H, Kitano S, Nakai K, Sasaki R, Kurisaki-Arakawa A, Arakawa A, Otsuji N, Matsuoka S, Tokuda E, Arai M, Saito M. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Cancer science. 2020.07; 111 (7): 2647-2654. ( PubMed, DOI )

  10. Horimoto Y, Terao T, Tsutsumi Y, Tanabe M, Mogushi K, Hlaing MT, Sasaki R, Saeki H, Okazaki M, Sonoue H, Arakawa A, Saito M. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification. The American journal of surgical pathology. 2019.09; 43 (9): 1221-1228. ( PubMed, DOI )

  11. Sasaki R, Horimoto Y, Mizuno J, Edahiro Y, Ohmori T, Komatsu N, Saito M. Administration of plasma-derived coagulation factor VIII during the perioperative period of mastectomy for breast cancer with acquired von Willebrand syndrome. Surgical case reports. 2018.09; 4 (1): 118. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. 王 子旭, 山下 和成, 佐々木 律子, 小名木 寛子, テキ ウビ, 九冨 五郎, 折茂 彰. ヒト乳がん関連線維芽細胞の増殖を抑制する化合物の同定(Identification of compounds that inhibit proliferation of tumor-promoting human breast cancer-associated fibroblasts). 日本癌学会総会記事 2025.09.01

  2. 佐々木律子, 江口英孝, 宮崎彩記子, 赤松和土, 齊藤光江. 乳癌患者由来iPS細胞モデルを用いた分子標的薬による心毒性メカニズムの解明(心疾患の発症機構解明と新たな治療戦略). 第101回日本生理学会大会 2024.03.30

  3. INVOLVEMENT OF KALLIKREIN-PAR2-PROINFLAMMATION PATHWAY IN TRSTUZUMAB-INDUCED SEVER CARDIOTOXICITY REVEALED BY PATIENT-SPECIFIC IPS CELL MODEL.. 2023.06.23

  4. ESTABLISHMENT OF IN VITRO EXPERIMNTAL MODEL SYSTEMS OF PATIENT-DERIVED IPSCS CARDIOMYOCYTE FOR EVALUATION OF TRASTUZUMAB-INDUCED SEVERE CARDIOTOXICITY. 2022.06.23

  5. 堀本 義哉, May Thinzar Hlaing , 佐伯 春美, 佐々木 律子, 荒川 敦, 齊藤 光江. 乳腺髄様癌におけるマイクロサテライトの不安定性の状況(Microsatellite instability status among medullary carcinoma of breast). 日本病理学会会誌 2020.03.01

To the head of this page.▲